P. Sevelda

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Martin Filipits, Margaretha Rudas, R. Jakesz et al. · Clinical Cancer Research · 2011 · 728 citations · Full text

Medicine, Cancer Biology, Oncology +17

Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma

Ignace Vergote, Jos De Brabanter, Anthony Fyles et al. · The Lancet · 2001 · 627 citations

Medicine, Oncology, Pathology +16

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

Michael Gnant, Georg Pfeiler, Peter Dubsky et al. · The Lancet · 2015 · 560 citations

Medicine, Oncology, Pharmacology +13

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Michael Gnant, Brigitte Mlineritsch, Herbert Stoeger et al. · Annals of Oncology · 2014 · 307 citations · Full text

Medicine, Oncology, Pharmacotherapy +16